| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Notman Donald | Chief Operating Officer | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD | /s/ Todd Anderman, Attorney-in-Fact for Donald Notman | 04 Feb 2026 | 0001718019 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OCUL | Common Stock | Sale | $49,859 | -5,455 | -1.4% | $9.14 | 383,837 | 02 Feb 2026 | Direct | F1, F2 |
| transaction | OCUL | Common Stock | Sale | $51,539 | -6,035 | -1.6% | $8.54 | 377,802 | 04 Feb 2026 | Direct | F3, F4 |
| Id | Content |
|---|---|
| F1 | Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sales instruction letter dated May 13, 2022, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 30, 2026. The sales do not represent a discretionary trade by the reporting person. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.0565 to $9.3217, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
| F3 | Represents shares of common stock of the Corporation sold, pursuant to a durable automatic sales instruction letter dated May 13, 2022, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 3, 2026. The sales do not represent a discretionary trade by the reporting person. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.4377 to $8.6769, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. |